anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sleep disorders significantly affect sleep duration and constitute a major public health issue. However, the relationship between metal exposure and sleep is not fully elucidated. This study utilized publicly available data from the National Health and Nutrition Examination Survey (NHANES) to measure blood concentrations of seven metals-copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), mercury (Hg), cadmium (Cd), and lead (Pb)-in a cohort of 4263 American adults. The relationship between metal exposure and self-reported sleep duration and sleep disorder risk was analyzed using single exposure models like logistic and linear regression and mixedexposure models such as weighted quantile sum (WQS) regression and Bayesian kernel machine regression (BKMR). The results indicated an absence of statistically significant findings in the single exposure model. In contrast, the mixed exposure model revealed a positive correlation between selenium levels and the risk of sleep disorders across the entire population. A "U-shaped" association was identified between copper levels and the risk of sleep disorders in males, females, and individuals aged 60 and above. Moreover, a positive trend was observed between manganese levels and the risk of sleep disorders in individuals aged 60 and above. Additionally, elevated concentrations of metal mixtures were significantly associated with reduced sleep duration among females. Sensitivity analyses corroborated these findings. In conclusion, within the context of metal mixtures, selenium may be a risk factor for sleep disorders in the general population. Manganese may be a unique risk factor in older adults. Copper levels have a "U" shaped link to sleep disorder risk in specific population subgroups. Finally, the accumulation of blood metal mixtures in females, mainly due to lead and mercury, may reduce sleep duration. Further research is necessary to validate these findings.
A process to refine esters of conjugated linoleic acids via distillation in a single or multi-pass distillation operation is provided. Thermal rearrangement of conjugated linoleic acid components during distillation is prevented or reduced by the use of a low residence time and/or reduced pressure distillation apparatus. A process to produce refined esters of conjugated linoleic acids is also provided. The process transesterifies a linoleic acid-containing oil to generate an alkyl ester composition which further undergoes isomerization at a temperatures typically between about 90-140 °C to form an ester stream containing conjugated linoleic acid esters, which is then distilled to obtain the refined esters of conjugated linoleic acids. The transesterification and isomerization steps can be performed in one reaction vessel without an intervening distillation step. The transesterification and isomerization steps can occur concurrently in a continuous reaction system using a dual reaction zone apparatus. Refined ester compositions produced by the processes and enriched in desirable conjugated linoleic acid isomers are also contemplated.
The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
AIMS: Both effective analgesia and early breastfeeding play an important role in maternal and neonatal well-being after Caesarean delivery. We studied controlled-release oxycodone tablet treatment for postoperative pain management and determined the excretion of oxycodone into breast milk.
METHODS: Controlled-release oxycodone/naloxone 10/5-mg tablets (n = 21) or controlled-release oxycodone 10-mg tablets (n = 22) were administered to mothers twice a day for the first 3 days after elective Caesarean delivery as a part of multimodal analgesia. Maternal plasma and breast milk samples were collected daily. Oxycodone, noroxycodone, oxymorphone and noroxymorphone concentrations were analysed with ultra-performance liquid chromatography-mass spectrometry. Maternal pain intensity was recorded with an 11-point Numeric Rating Scale (0-10). Neonatal oxycodone exposure was estimated by simulating five different exposure scenarios, including the highest possible exposure through breast milk.
RESULTS: The mean oxycodone and noroxycodone milk-to-maternal plasma ratios were 3.2 and 3.0, respectively. A strong correlation was found between plasma and breast milk oxycodone (R2 = 0.87) and noroxycodone concentrations (R2 = 0.91). In the simulated highest neonatal exposure scenario, the neonate's maximum plasma concentration was estimated to be 5.4 ng/mL and the estimated weight-adjusted infant oxycodone dose was less than 10% of the maternal dose. Pain intensities were similarly low between the two treatment groups.
CONCLUSIONS: The oxycodone dose received from colostrum and breast milk during the first three postoperative days after Caesarean delivery is assumed safe for healthy, term neonates, but in extreme cases it is possible for the neonate to receive a dose through breast milk that may elicit opioid effects.
BACKGROUND: Next-generation sequencing (NGS) has significantly transformed the landscape of identifying disease-causing genes associated with genetic disorders. However, a substantial portion of sequenced patients remains undiagnosed. This may be attributed not only to the challenges posed by harder-to-detect variants, such as non-coding and structural variations but also to the existence of variants in genes not previously associated with the patient's clinical phenotype. This study introduces EvORanker, an algorithm that integrates unbiased data from 1,028 eukaryotic genomes to link mutated genes to clinical phenotypes.
METHODS: EvORanker utilizes clinical data, multi-scale phylogenetic profiling, and other omics data to prioritize disease-associated genes. It was evaluated on solved exomes and simulated genomes, compared with existing methods, and applied to 6260 knockout genes with mouse phenotypes lacking human associations. Additionally, EvORanker was made accessible as a user-friendly web tool.
RESULTS: In the analyzed exomic cohort, EvORanker accurately identified the "true" disease gene as the top candidate in 69% of cases and within the top 5 candidates in 95% of cases, consistent with results from the simulated dataset. Notably, EvORanker outperformed existing methods, particularly for poorly annotated genes. In the case of the 6260 knockout genes with mouse phenotypes, EvORanker linked 41% of these genes to observed human disease phenotypes. Furthermore, in two unsolved cases, EvORanker successfully identified DLGAP2 and LPCAT3 as disease candidates for previously uncharacterized genetic syndromes.
CONCLUSIONS: We highlight clade-based phylogenetic profiling as a powerful systematic approach for prioritizing potential disease genes. Our study showcases the efficacy of EvORanker in associating poorly annotated genes to disease phenotypes observed in patients. The EvORanker server is freely available at https://ccanavati.shinyapps.io/EvORanker/ .
1. Use of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells resulting in the protection from graft rejection by a host's immune system. 2. Use as claimed in claim 1, wherein the DNA encoding a LAG-3 protein is exogenous. 3. Use as claimed in claim 1, wherein the DNA encoding a LAG-3 protein is endogenous and its expression is activated or modified through the targeted insertion of a regulator sequence and/or an amplifiable gene by homologous recombination. 4. Use as claimed in any of claims 1 to 3, wherein said cells are part of a tissue or organ to be transplanted. 5. Use as claimed in any of claims 1 to 3, wherein said cells are gene therapy host cells. 6. Use as claimed in claim 5, wherein gene therapy is somatic or "ex vivo" gene therapy. 7. Use as claimed in any of claims 1 to 6, wherein said cells are derived from transgenic animals. 8. Use as claimed in any of claims 1 to 7, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 9. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells and an additional immuno-suppressive agent, such as IL-10. TGFss or Fas ligand resulting in the protection from graft rejection by a host's immune system. 10. Use as claimed in claim 9, wherein said cells are derived from transgenic animals. 11. Use as claimed in claim 9 or 10, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 12. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells and the thymidine Kinase (tk) gene to be sensitive to the tk-gancyclovir suicide system resulting in the protection from graft rejection by a host's immune system. 13. Use as claimed in claim 12, wherein said cells are derived from transgenic animals. 14. Use as claimed in claim 12 or 13, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 15. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells in the manufacture of a medicament to induce protection from graft rejection by a host's immune system.
PURPOSE: To miniaturize the work machine by using in common parts of a work machine moving mechanism by constituting the mechanism so that by an ascending/descending block being movable vertically, a machine supporting block can be subjected to reciprocating rotation at a prescribed angle in the horizontal direction, and a ball spline can turn the machine supporting block in the shaft rotating direction. CONSTITUTION: When a work machine 2 completes a work to a work 10, a third cylinder 9 allows an ascending/descending block 4 to descend to the lower limit. The work machine 2 separates from the work 10. A second cylinder 8 rotates a ball spline by a prescribed angle in the left direction. By this rotation, a machine supporting block 3 and the whole unit supported thereby are rotated and oscillated, and the work machine 2 is saved to a prescribed position separated enough from the work 10. Another work machine 11 moves to a work position in which the work 10 exists and executes a work. The work machine 2 can be miniaturized because a guide shaft for moving forward and backward and a rotation driving shaft are used in common by one piece of ball spline [JPS5337653A]
PURPOSE:A remedy for effective for the remedy of keloid, etc. which is a hydrophilic ointment containing specific multiamino acids, e.g. arginine, histidine, etc. in a high concentration. CONSTITUTION:A remedy for scars consisting of a hydrophilic ointment containing 20-50wt% multiamino acids consisting of arginine, histidine, isoleucine, lysine, threonine, valine, alanine, proline, tyrosine, serine, aspartic acid and glutamic acid or a salt thereof. Scalds or wounds leave scars, e.g. hypertrophic scars or keloids, and the remedy thereof is very difficult. The application of the hydrophilic ointment has the effects of softening the scars, removing the redness, smoothing the scars and eliminating the itching feeling.
The renin-angiotensin system (RAS) is known to affect diverse physiological processes that affect the functioning of many key organs. Angiotensin-converting enzyme (ACE) modulates a variety of bioactive peptides associated with pain. ACE inhibitors (ACEis) have found applications in the treatment of cardiovascular, kidney, neurological and metabolic disorders. However, ACEis also tend to display undesirable effects, resulting in increased pain sensitization and mechanical allodynia. In this review, we provide comprehensive discussion of preclinical and clinical studies involving the evaluation of various clinically approved ACEis. With the emerging knowledge of additional factors involved in RAS signaling and the indistinct pharmacological role of ACE substrates in pain, extensive studies are still required to elucidate the mechanistic role of ACE in pain perception.
PROBLEM TO BE SOLVED: To obtain a dentifrice composition capable of foaming by brushing and brushing teeth for a long period without dripping the foam from a mouth even when brushing the teeth for the long period due to a slight reduction in viscosity of the foam even when diluted with saliva. SOLUTION: This dentifrice composition contains 0.5-20 wt.% of a surfactant, e.g. a fatty acid ester of a sugar (alcohol), 1-3 wt.% of a binder, e.g. xanthan gum, 10-70 wt.% of a humectant, e.g. glycerol, 5-70 wt.% of a polishing agent, e.g. calcium secondary phosphate dihydrate and 10-50 wt.% of water and is capable of foaming by brushing and causing a slight reduction in viscosity of the foam even when diluted with saliva. The value of complex modulus of elasticity G* obtained by a dynamic viscoelastic measurement of the foam produced by brushing is >=300 dyne/cm2, preferably 300-600 dyne/cm2 and the value of dynamic loss tangent tanδ is preferably 0.5-1.5.
The planned number of Chinese cohorts is 1, but more than 1 cohort may be included if it is considered necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Chinese cohort.
BACKGROUND: We conducted a comparative analysis of hypertension prevalence, progression, and treatment in two Finnish population-based cohorts comprising older adults born 20 years apart. The study covered data from pre- and post-HYVET Study eras and spanned the onset of the COVID-19 pandemic.
METHODS: All 70-year-old home-dwelling citizens of Turku, in Southwest Finland, were invited to participate in the survey in 1990 (1920-born TUVA cohort) and in 2010 (1940-born UTUVA cohort) with a 25-year follow-up plan. The analyses included those with available data for systolic and diastolic blood pressure (BP), yielding 1015 TUVA and 888 UTUVA participants at baseline. Biomarkers associated with BP were analysed with t- and chi-square tests.
RESULTS: At baseline, 83.4% of TUVA and 74.3% of UTUVA participants had uncontrolled BP, with respective antihypertensive medication usage at 36.0% and 55.9% (p < .001 for both between-cohort differences). Systolic BP exhibited an inverted U-shaped trajectory, with TUVA initially 7.8 mmHg higher at 155.4 mmHg than UTUVA (p < .001). However, by the ages 80-82, the difference in systolic BP trajectories between the cohorts was attenuated to 4.0 mmHg (p = .03). Diastolic BP differences were less clinically significant. UTUVA demonstrated higher use of all five conventional antihypertensive categories than TUVA (p ≤ .02 for all categories).
CONCLUSIONS: In the early years of older adulthood, the 1940-born cohort showed a positive trend in hypertension management, yet maintained a 74.3% baseline rate of uncontrolled BP. Furthermore, by the ages 81-82, the benefits observed over the 1920-born cohort had lessened, influenced by the COVID-19 pandemic or other lasting factors. Heightened efforts to improve hypertension treatment in older adults remain crucial in the post-HYVET era.
The invention discloses a fructus chebulae immaturus extract, a fructus chebulae immaturus extract monomer compound and application thereof in inhibiting monoamine oxidase B activity. Fructus chebulae immaturus (Terminalia chebula Retz.) extract XQG-EA-7 is the portion of fructus chebulae immaturus methanol extract extracted sequentially with petroleum ether and ethyl acetate, and the obtained ethyl acetate portion is separated by normal phase column dichloromethane-acetone-formic acid system gradient elution, and the portion of the obtained components with the strongest activity for inhibiting monoamine oxidase B is obtained. The 5 monomeric compounds of the fructus chebulae immaturus extract are obtained by separating the fructus chebulae immaturus extract through a reverse phase column; the separation system is a medium-pressure glass chromatographic column and is obtained by gradient elution in a water-methanol system. The invention provides the use of the above-mentioned fructus chebulae immaturus extract and 5 monomeric compounds of fructus chebulae immaturus extract in inhibiting monoamine oxidase B activity. The invention also provides an HPLC identification method of the monomer compound XQG-EA-7-6.
Sleep deprivation (SD) has emerged as a critical concern impacting human health, leading to significant damage to the cardiovascular system. However, the underlying mechanisms are still unclear, and the development of targeted drugs is lagging. Here, we used mice to explore the effects of prolonged SD on cardiac structure and function. Echocardiography analysis revealed that cardiac function was significantly decreased in mice after five weeks of SD. Real-time quantitative PCR (RT-q-PCR) and Masson staining analysis showed that cardiac remodeling marker gene Anp (atrial natriuretic peptide) and fibrosis were increased, Elisa assay of serum showed that the levels of creatine kinase (CK), creatine kinase-MB (CK-MB), ANP, brain natriuretic peptide (BNP) and cardiac troponin T (cTn-T) were increased after SD, suggesting that cardiac remodeling and injury occurred. Transcript sequencing analysis indicated that genes involved in the regulation of calcium signaling pathway, dilated cardiomyopathy, and cardiac muscle contraction were changed after SD. Accordingly, Western blotting analysis demonstrated that the cardiac-contraction associated CaMKK2/AMPK/cTNI pathway was inhibited. Since our preliminary research has confirmed the vital role of Casein Kinase-2 -Interacting Protein-1 (CKIP-1, also known as PLEKHO1) in cardiac remodeling regulation. Here, we found the levels of the 3' untranslated region of Ckip-1 (Ckip-1 3'UTR) decreased, while the coding sequence of Ckip-1 (Ckip-1 CDS) remained unchanged after SD. Significantly, adenovirus-mediated overexpression of Ckip-1 3'UTR alleviated SD-induced cardiac dysfunction and remodeling by activating CaMKK2/AMPK/cTNI pathway, which proposed the therapeutic potential of Ckip-1 3'UTR in treating SD-induced heart disease.
A process for the manufacture of new crystalline salts of N-[2-(dimethylamino)ethyl]-1,2-dithiolane-3-pentanamide (racemic and chiral forms) is described. Such salts are stable, crystalline and have very good solubility in water. The salts exhibit antioxidant properties. They inhibit collagenase and elastase enzymes. They have excellent anti acne activity in addition tyrosinase inhibition. They are, by themselves and in combination with other known agents, important cosmetic ingredients.
FIELD: medicine.SUBSTANCE: group of inventions relates to neurology and concerns using a therapeutically effective amount of a composition for preparing a medicament for stimulating remyelination of neurons in a mammal, wherein said neurons are demyelinated by cell respiration disorders. Composition contains a.) water of pharmaceutical category; b.) at least one processing amplifier selected from a group of materials consisting of sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium triphosphate, sodium diphosphate, sodium monophosphate and potassium phosphates; and c.) gold nanocrystals, suspended in said water to form a suspension. Said nanocrystals: i.) have surfaces which include at least one characteristic selected from a group of characteristics consisting of: (1) organic chemical components are not attached to or do not stick to said surfaces, and/or (2) they have a clean surface and have no chemical components attached or adhered to surfaces other than water or said processing amplifier, which change operation of said nanocrystals; ii.) have a particle size modulus of less than 50 nm; iii.) are present in said suspension in concentration of 2–3000 ppm; and d.) said suspension has pH of 5 to 9.5 and a zeta potential of at least -30 mV. Also presented is using a therapeutically effective amount of the nanosuspension for preparing a medicinal agent for treating a disease in a mammal, including neuron demyelination caused by cellular respiration disorder in said neurons, wherein said drug stimulates remyelination of said neurons.EFFECT: group of inventions provides stimulating neuronal remyelination in a mammal, wherein said neurons are demyelinated by cell respiration disorder, wherein the composition contains elementary gold nanosuspension.12 cl, 51 dwg, 5 tbl, 3 ex
The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
Chronic hepatitis B (CHB) remains a serious threat to people's health. As of 2019, approximately 296 million people (3.9% of the world's population) were infected with the HBV virus. In the treatment of CHB, Antiviral drugs can not only achieve long-term viral suppression for most CHB patients, but also have a positive impact on other CHB treatment goals and improvement of prognosis, but can not eliminate the risk of adverse clinical outcomes completely, which are partly attributed to concomitant diseases such as fatty liver disease (FLD). Both diseases can cause chronic liver injure and increase the risk of cirrhosis and HCC.All patients included in this study underwent liver biopsy to determine their pathological status, ensuring the reliability and accuracy of disease diagnosis. And based on biopsy results, patients were categorized into two groups:fatty liver combined with hepatitis B and hepatitis B alone. The main antiviral treatments used in the study include first-line NAs, such as entecavir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), and interferons (IFN-α and Peg-IFN-α). They were followed for five years to thoroughly assess the long-term efficacy of antiviral treatment. Additionally, complications and liver fibrosis were evaluated using ultrasound and FibroScan to monitor the advancement of liver disease.